The estimated Net Worth of Christopher M Hall is at least $1.24 Milione dollars as of 1 November 2023. Christopher Hall owns over 20,459 units of Personalis Inc stock worth over $1,217,019 and over the last 11 years Christopher sold PSNL stock worth over $19,027.
Christopher has made over 15 trades of the Personalis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Christopher sold 20,459 units of PSNL stock worth $19,027 on 1 November 2023.
The largest trade Christopher's ever made was exercising 115,000 units of Personalis Inc stock on 6 May 2019 worth over $840,650. On average, Christopher trades about 15,518 units every 137 days since 2014. As of 1 November 2023 Christopher still owns at least 204,541 units of Personalis Inc stock.
You can see the complete history of Christopher Hall stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci e Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: